Literature DB >> 9322101

The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.

B Rizk1, M Aboulghar, J Smitz, R Ron-El.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is a dramatic complication of ovulation induction. In its most severe form, OHSS is characterized by massive cystic enlargement of the ovaries associated with third space fluid shift, resulting in the formation of ascites and pleural effusion. Ascites developes because of increased peritoneal capillary permeability. In this study we examined the role of vascular endothelial growth factor (VEGF) and interleukins in the pathogenesis of increased capillary permeability. VEGF is a member of the family of heparin binding proteins that act directly on endothelial cells to induce proliferation and angiogenesis. VEGF mRNA and protein are expressed by human ovarian granulosa and theca cells late in follicular development and subsequent to ovulation by granulosa and theca cells. Therefore, VEGF is ideally positioned to provoke the increased permeability of theca blood vessels that occurs shortly before ovulation. Hybridization studies in the rat and primate ovary have demonstrated VEGF mRNA expression predominantly after the luteinizing hormone (LH) surge known to be essential for OHSS. The gonadotrophin-releasing hormone antagonist results in a decreased mRNA expression, implying such expression is dependent on LH. The expression of VEGF mRNA has been recently shown to be enhanced by human chorionic gonadotrophin (HCG) in a dose- and time-dependent fashion. These studies confirm the timely association between VEGF and HCG that has been clinically known for many years to be integral in the development of OHSS. VEGF concentrations in serum, peritoneal fluid and follicular fluid of patients at risk for OHSS have been shown to be significantly related to the development of the syndrome. Furthermore, the kinetics of VEGF in the plasma of patients who actually develop severe OHSS are closely correlated with the clinical course of the syndrome and with certain biological characteristics of OHSS and of capillary leakage, such as leukocytosis and increased hematocrit. Studies on ascitic fluid from patients with sever OHSS have proved that VEGF is the major capillary permeability agent. Incubation with VEGF antiserum decreased the vascular permeability activity by 70%. Interleukin-2 (IL-2) is the first of a series of lymphocytotrophic hormones to be recognized as pivotal for the regulation of immune response. However, hard data to confirm its central role in the pathogenesis of OHSS are still lacking, despite the fact that some preliminary studies suggest a positive association between the pooled follicular fluid IL-2 concentration and the development of OHSS. IL-6 is a mediator of the acute phase response to injury, a systemic reaction characterized by leukocytosis, increased vascular permeability and increased synthesis of acute phase proteins by the liver. Significantly higher serum and ascites IL-6 concentrations were seen in OHSS patients. The immunohistochemical localization pattern suggested that IL-6 is LH or HCG dependent. However, the use of IL-6 as a predictor for the occurrence of OHSS has not been successful. The kinetics of IL-6 in patients with severe OHSS are correlated with the clinical symptoms and the biochemical parameters known to be associated with the severity of the syndrome, suggesting a possible role for IL-6. Further molecular biology studies similar to those performed on VEGF are needed to confirm if this interleukin is central in the cascade of events. IL-8 is a chemoattractant, activating cytokine and a potent angiogenic agent. The peritoneal fluid levels is increased in patients with severe OHSS; its concentration in peritoneal fluid is increased inpatients with severe OHSS. The place of this interleukin in the cascade of events is as yet undetermined and further studies are needed. In conclusion, molecular biology and clinical studies strongly suggest that VEGF is the principal mediator by which HCG might increase capillary permeability in OHSS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322101     DOI: 10.1093/humupd/3.3.255

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  34 in total

1.  Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury.

Authors:  Ozlem U Gurkan; Chaoxia He; Rachel Zielinski; Hamid Rabb; Landon S King; Jeffrey M Dodd-o; Franco R D'Alessio; Neil Aggarwal; David Pearse; Patrice M Becker
Journal:  Exp Lung Res       Date:  2011-11-01       Impact factor: 2.459

2.  Spontaneous Severe Ovarian Hyper Stimulation Syndrome Associated with Massive Pericardial Effusion and Hypothyroidism in Non-pregnant Woman.

Authors:  Amit Singh; Kumkum Singh; Radha Govind Khandelwal; Prakash Choudhary; Vivek Kumar Sharma
Journal:  J Obstet Gynaecol India       Date:  2014-10-08

3.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

Review 4.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

5.  Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume.

Authors:  Tomoko Inoue; Shu Hashimoto; Hideyuki Iwahata; Keijiro Ito; Yoshiharu Nakaoka; Yoshiharu Morimoto
Journal:  Reprod Med Biol       Date:  2014-11-11

6.  Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome.

Authors:  Lan Wang; Hemei Li; Jihui Ai; Jing Yue; Zhou Li; Hanwang Zhang; Yiqing Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

7.  Rare genetic variants potentially involved in ovarian hyperstimulation syndrome.

Authors:  Katrien Stouffs; Sari Daelemans; Samuel Santos-Ribeiro; Sara Seneca; Alexander Gheldof; Ali Sami Gürbüz; Michel De Vos; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2018-11-27       Impact factor: 3.412

Review 8.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

9.  The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Cristiano Busso; Manuel Fernández-Sánchez; Juan Antonio García-Velasco; José Landeras; Augustín Ballesteros; Elkin Muñoz; Sandra González; Carlos Simón; Joan-Carles Arce; Antonio Pellicer
Journal:  Hum Reprod       Date:  2010-02-06       Impact factor: 6.918

10.  Pseudo-Meigs' syndrome secondary to metachronous ovarian metastases from transverse colon cancer.

Authors:  Kennoki Kyo; Atsushi Maema; Motoaki Shirakawa; Toshio Nakamura; Kenji Koda; Hidetaro Yokoyama
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.